Should all sleep apnoea patients be treated?

Area of Science:

• Sleep Medicine
• Respiratory Medicine
• Cardiovascular Health

Background:

• Sleep apnoea is a condition with breathing cessation during sleep, affecting 20% of populations with an apnoea-hypopnoea index (AHI) >10.
• Sleep apnoea hypopnoea syndrome (SAHS) affects 4% of people, presenting with symptoms like daytime sleepiness and non-refreshing sleep.
• SAHS has significant health and social impacts, necessitating effective management strategies.

Purpose of the Study:

• To review the effectiveness of nasal continuous positive airway pressure (nCPAP) in treating SAHS.
• To address the challenge of treating SAHS, particularly in patients with varying symptom severity.
• To investigate the role of nCPAP in individuals with high AHI but minimal or no symptoms.

Main Methods:

• Literature review of epidemiological studies on sleep apnoea prevalence.
• Analysis of clinical studies evaluating nCPAP efficacy in symptomatic SAHS patients.
• Examination of research on the effects of high AHI in asymptomatic individuals.

Main Results:

• nCPAP is proven effective for moderate to severe symptomatic SAHS.
• Approximately 15% of the general population has a high AHI (>10) without noticeable symptoms.
• High AHI, even without symptoms, is linked to increased risks of traffic accidents and cardiovascular issues.

Conclusions:

• nCPAP is a well-supported treatment for symptomatic SAHS.
• Further research is needed to establish optimal nCPAP treatment thresholds for varying symptom levels.
• Comprehensive studies are warranted to define nCPAP's role in asymptomatic individuals with high AHI.